Moderna strikes deal to develop mRNA drugs in China

Nikos Pekiaridis | Nurphoto | Getty Images

Moderna on Wednesday said it struck a take care of Chinese officials to research, develop and manufacture messenger RNA medicines within the country, despite rising tensions between the U.S. and China. 

The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop drugs that may “be exclusively for the Chinese people” and won’t “be exported,” a Moderna spokesperson told CNBC.  

Chinese media outlet Yicai first reported on Tuesday that Moderna was slated to make its first investment in China that may very well be price around $1 billion, citing unnamed sources. The outlet also reported that Moderna CEO Stéphane Bancel was visiting Shanghai. 

The Moderna spokesperson didn’t confirm the report or comment on the dimensions of the deal.

“These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China,” the spokesperson said. 

Moderna is attempting to capitalize on the success of its Covid vaccine, which uses a platform called mRNA to show human cells to provide an immune response against a virus.

Moderna has several contracts to export or locally manufacture Covid jabs for countries comparable to Japan, Canada, Australia and Kenya. The deal disclosed Wednesday is the corporate’s first agreement with China.

It is also the primary deal to involve developing mRNA medicines overall, not only Covid shots. 

Moderna in May said it was keen to sell its mRNA Covid vaccine to China after registering a legal entity on the planet’s second-largest economy. 

But the corporate and other U.S.-based corporations have to this point been shut out from the Chinese market.

Beijing has repeatedly insisted on using Chinese-made Covid vaccines for its population, despite the fact that their shots are seen as less effective than jabs from Moderna and Recent York-based Pfizer. 

The country has also struggled to develop mRNA technology at home in the course of the pandemic. China only approved its first mRNA shot earlier this 12 months.

Individually on Wednesday, China’s Ministry of Commerce said it held a gathering with a number of the world’s leading drugmakers to debate their business operations within the country.

That features Pfizer, AstraZeneca, Novo Nordisk, Merck, Sanofi and GE HealthCare Technologies. It’s unclear whether Moderna was included within the rountable discussion.

Moderna’s deal comes as tensions between the U.S. and China rise over issues starting from national security to a heavy reliance on Chinese supply chains. The Biden administration has taken aggressive measures to diversify away from China in investment and trade.